Combined Measurements of Cardiac Troponin I and Brain Natriuretic Peptide Are Useful for Predicting Adverse Outcomes in Hypertrophic Cardiomyopathy
Authors:
Open Access
- 1 January 2011
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (4) , 919-926
Abstract
Background: Although serum cardiac troponin I (cTnI) and plasma brain natriuretic peptide (BNP) have become clinically important tools as diagnostic and prognostic markers for ischemic heart disease and heart failure, the usefulness of these biomarkers for risk stratification of hypertrophic cardiomyopathy (HCM) is not clear. Methods and Results: We studied 167 patients with HCM, and cTnI and BNP were measured. During follow-up (38.5 months), 20 patients suffered from cardiovascular events: HCM-related deaths in 6, hospitalization for heart failure in 8, embolic stroke in 5 and 1 patient with spontaneous sustained ventricular tachycardia. Patients with high cTnI values (≥0.04ng/ml) had more frequent cardiovascular events than did those with low cTnI values (P=0.008). Similarly, there were more frequent adverse events in the high BNP group (≥200pg/ml) than in the low BNP group (P=0.002). When groups were allocated according to both cTnI and BNP measurements, serum cTnI used in conjunction with BNP further improved the prognostic value; patients with both high cTnI and BNP values had an 11.7-fold increased risk of cardiovascular events compared with those with both low cTnI and BNP values. Conclusions: CTnI and BNP are useful parameters for identifying patients at risk for clinical deteriorations, and combined measurements of these biomarkers further improves the prognostic value of increased cardiovascular events in HCM. (Circ J 2011; 75: 919-926)Keywords
This publication has 25 references indexed in Scilit:
- Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathyEuropean Heart Journal, 2009
- Molecular Etiology and Pathogenesis of Hereditary CardiomyopathyCirculation Journal, 2008
- Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deteriorationJACC, 2003
- Hypertrophic CardiomyopathyJAMA, 2002
- Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathyThe Lancet, 2001
- Epidemiology of Hypertrophic Cardiomyopathy–Related DeathCirculation, 2000
- Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic CardiomyopathyNew England Journal of Medicine, 2000
- Clinical Course of Hypertrophic Cardiomyopathy in a Regional United States CohortJAMA, 1999
- The Management of Hypertrophic CardiomyopathyNew England Journal of Medicine, 1997
- Hypertrophic cardiomyopathy in tuscany: Clinical course and outcome in an unselected regional populationJACC, 1995